TEL
AVIV, Israel, July 8, 2024
/PRNewswire/ -- Vectorious Medical Technologies Ltd.
announces the publication of a breakthrough pilot clinical
study, which evaluated the V-LAP system and a novel therapeutic
approach for heart failure, in the European Journal of Heart
Failure.
Vectorious has developed a miniature digital pressure sensor
(V-LAP) that measures left atrial pressure and is implanted in the
heart's interatrial septum using a minimally invasive
catheterization procedure. The sensor transmits data that allows
physician-directed, patient self-management of chronic heart
failure, a prevalent and complex form of heart disease affecting
approximately 1-2% of the population. Through a dedicated mobile
application and based on daily data transmitted from the left
atrium, patients self-adjust their diuretic dosage with the aim of
preventing disease deterioration and repeated hospitalizations.
The study demonstrated for the first time that self-management
of heart failure based on left atrial pressure (LAP) is both safe
and feasible. At 12 months of follow-up, no complications or side
effects related to the system were reported. Additionally, patient
adherence to treatment was high, and significant improvements were
observed in quality-of-life measures, coupled with a reduction in
hospitalizations due to heart failure.
"This groundbreaking study marks a significant milestone in
heart failure management by placing control directly in the hands
of patients. This approach, akin to the empowerment seen in
diabetes management, enables heart failure patients, under the
guidance of their heart failure management team, to monitor and
manage their condition safely with ease and confidence. By
fostering greater patient autonomy, this innovative shift is set to
dramatically enhance care quality and outcomes for this vulnerable
population." Said David Meerkin, MBBS, Interventional
Cardiologist participating in the pilot VECTOR-HF study.
To date, 55 V-LAP sensors have been successfully implanted in
patients across Europe and
Israel, accumulating over 40,000
days of LAP monitoring. This summer, implantations are planned to
begin in leading heart centers in the
United States, marking the next phase in the expansion of
Vectorious' clinical trials.
"This study marks another significant step in realizing the
transformative potential of patient self-management guided by left
atrial pressure monitoring. By empowering patients with real-time
hemodynamic data and decision-making tools, this innovative
approach may not only enhance patient-centered outcomes but also
shift the paradigm towards proactive and personalized heart failure
care." Said William T Abraham, Professor of Medicine from
The Ohio State University Wexner
Medical Center and one of the pioneers in implantable hemodynamic
monitoring systems for heart failure patients.
Eyal Orion, co-founder and CEO of
Vectorious, added: "Publishing the research in a top-tier
scientific journal is a historic milestone for the company, which
has been developing not only one of the most complex medical
systems but also a new therapeutic approach for over a decade.
Transferring part of the responsibility to patients requires
advanced, reliable, and accurate technology, and this is a
challenge that requires perseverance and patience. We still have a
way to go to fundamentally change the way the most common heart
disease is understood and treated, but together with the amazing
Vectorious team, physicians, and our partners, we are getting
closer step by step."
About Vectorious Medical Technologies Ltd.
Vectorious is a privately held company based in
Tel Aviv, Israel, founded in 2011.
The company's V-LAP System enables heart failure patients to better
control their disease by monitoring the heart's Left Atrial
Pressure (LAP) and detecting fluid accumulation in the earliest
stages of the disease, prior to physiological symptoms. A mobile
app further empowers patients to self-titrate medication in
real-time based on data extracted from the heart. For more
information, please visit the company website.
Contact:
Lili Arbely-Elbaz
Vectorious Medical Technologies.
+972-(0)525909192
lili@vectoriousmedtech.com
Photo -
https://mma.prnewswire.com/media/2455810/Vectorious_V_LAP.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/vectorious-medical-technologies-reports-novel-findings-from-vector-hf-trials-self-management-of-heart-failure-patients-using-left-atrial-pressure-302190759.html
SOURCE Vectorious Medical Technologies Ltd.